Ginkgo Bioworks. has been granted a patent for adeno-associated virus (AAV) vectors featuring modified capsid proteins. The patent includes methods for administering these vectors to cells or subjects in vivo, specifically highlighting a capsid protein with the amino acid sequence of SEQ ID NO: 180. GlobalData’s report on Ginkgo Bioworks gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ginkgo Bioworks, was a key innovation area identified from patents. Ginkgo Bioworks's grant share as of June 2024 was 25%. Grant share is based on the ratio of number of grants to total number of patents.
Modified aav capsid proteins and virus vectors
The granted patent US11981914B2 outlines a novel adeno-associated virus (AAV) vector characterized by a specific AAV capsid protein, defined by the amino acid sequence of SEQ ID NO: 180. The claims detail the composition of the AAV vector, which includes a cargo nucleic acid encapsidated by the capsid protein. This cargo nucleic acid can contain terminal repeat sequences and may encode various types of heterologous nucleic acid sequences, including therapeutic polypeptides, immunogenic polypeptides, and nucleases such as Cas9 and Cas12 variants. Additionally, the cargo may encode untranslated RNAs, such as guide RNAs or interfering RNAs, which can play significant roles in gene editing and regulation.
The patent further describes a pharmaceutical composition that incorporates the AAV vector along with a pharmaceutically acceptable carrier, as well as methods for introducing the cargo nucleic acid into cells using the AAV vector. It also includes claims related to the AAV capsid protein itself, nucleic acids encoding this protein, and expression vectors containing such nucleic acids. A method for producing the AAV vector is also detailed, which involves culturing cells that contain the necessary nucleic acids and AAV sequences to facilitate the replication and encapsidation of the vector. This patent presents a comprehensive framework for the development and application of AAV vectors in therapeutic contexts, particularly in gene therapy and genetic engineering.
To know more about GlobalData’s detailed insights on Ginkgo Bioworks, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
